Transcriptomics

Dataset Information

0

Gene expression profiling of KU812 CD25 shRNA vs KU812 control random shRNA


ABSTRACT: In chronic myeloid leukemia (CML) neoplastic stem cells (NCS) represent a critical target of therapy. However, little is known about markers and targets expressed in CML NSC. We examined the phenotype and function of CD34+/CD38─/Lin─ CML LSC by a multi-parameter screen approach employing antibody-phenotyping, mRNA expression profiling, and functional studies, followed by marker-validation using diverse control-cohorts and follow-up samples of CML patients treated with imatinib. We here show that in contrast to normal stem cells, CD34+/CD38− CML NSC express IL2RA (CD25), and that STAT5 induces expression of CD25 in Lin−/Sca-1+/Kit+ NSC (LSK) in C57/Bl6 mice. Correspondingly, expression of CD25 decreased in the human BCR/ABL1+ stem cell line KU812 upon shRNA-induced STAT5-depletion. The BCR/ABL1-inhibitors nilotinib and ponatinib were also found to decrease STAT5 activity and CD25-expression in KU812 cells and primary CML NSC. A CD25-targeting shRNA augmented the proliferation of KU812 cells in vitro and in vivo in NOD/SCID-IL2R-/- mice. In consecutive experiments the PI3K/mTOR-blocker BEZ235 was found to promote STAT5- and CD25 expression and to produce synergistic anti-neoplastic effects with nilotinib and ponatinib in CML cells. Together, CD25 is a novel STAT5-dependent marker and target in CML NSC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE60315 | GEO | 2016/01/26

SECONDARY ACCESSION(S): PRJNA258011

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2018-05-24 | GSE103908 | GEO
2014-04-17 | GSE40721 | GEO
2014-04-17 | E-GEOD-40721 | biostudies-arrayexpress
2014-10-07 | E-GEOD-62121 | biostudies-arrayexpress
2023-11-15 | GSE226360 | GEO
2014-10-07 | GSE62121 | GEO
2009-05-12 | GSE16042 | GEO
2017-09-01 | GSE78037 | GEO
| EGAS00001001150 | EGA
2016-09-01 | E-GEOD-78037 | biostudies-arrayexpress